Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
3.220
-0.050 (-1.53%)
At close: May 13, 2025, 4:00 PM
3.260
+0.040 (1.24%)
Pre-market: May 14, 2025, 8:41 AM EDT
Protara Therapeutics Employees
As of December 31, 2024, Protara Therapeutics had 33 total employees, including 28 full-time and 5 part-time employees. The number of employees increased by 6 or 22.22% compared to the previous year.
Employees
33
Change (1Y)
6
Growth (1Y)
22.22%
Revenue / Employee
n/a
Profits / Employee
-$1,376,212
Market Cap
118.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33 | 6 | 22.22% |
| Dec 31, 2023 | 27 | 2 | 8.00% |
| Dec 31, 2022 | 25 | -6 | -19.35% |
| Dec 31, 2021 | 31 | 4 | 14.81% |
| Dec 31, 2020 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TARA News
- 1 day ago - Protara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 days ago - Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 12 days ago - Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - GlobeNewsWire
- 21 days ago - Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 - GlobeNewsWire
- 4 weeks ago - Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer - GlobeNewsWire
- 4 weeks ago - Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting - GlobeNewsWire
- 6 weeks ago - Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results - Seeking Alpha